MX2022006535A - Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. - Google Patents
Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.Info
- Publication number
- MX2022006535A MX2022006535A MX2022006535A MX2022006535A MX2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A
- Authority
- MX
- Mexico
- Prior art keywords
- psychological symptoms
- treating behavioral
- dementia patients
- sub
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente invención proporciona un método para tratar síntomas de comportamiento y psicológicos en paciente con demencia que comprende administrar una dosis efectiva de antagonista receptor de 5-HT6 puro, masupiridina o una sal farmacéuticamente aceptable de los mismos ya sea solos o en combinación con inhibidor de acetilcolinesterasa tal como donepezil y antagonista receptor de NMDA (N-Metil-D-aspartato), memantina; la presente invención además proporciona uso de dicho compuesto en la fabricación de un medicamento y composiciones farmacéuticas que comprenden dichos compuestos hechos para el tratamiento de los trastornos aquí descritos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201941049517 | 2019-12-02 | ||
IN201941049516 | 2019-12-02 | ||
PCT/IB2020/061383 WO2021111330A1 (en) | 2019-12-02 | 2020-12-02 | Treating behavioral and psychological symptoms in dementia patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006535A true MX2022006535A (es) | 2022-09-09 |
Family
ID=74003821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006535A MX2022006535A (es) | 2019-12-02 | 2020-12-02 | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220409614A1 (es) |
EP (1) | EP4069232A1 (es) |
JP (1) | JP2023506724A (es) |
KR (1) | KR20220108123A (es) |
CN (1) | CN114901282A (es) |
AU (1) | AU2020398082A1 (es) |
BR (1) | BR112022010493A2 (es) |
CA (1) | CA3162952A1 (es) |
IL (1) | IL293416A (es) |
MX (1) | MX2022006535A (es) |
WO (1) | WO2021111330A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4559230B2 (ja) | 2002-11-28 | 2010-10-06 | スベン ライフ サイエンシズ リミティド | セロトニン受容体に対する親和性を有する新規n−アリールスルホニル−3−置換されたインドール、その調製方法、それを含有する医薬組成物 |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
AU2012271068A1 (en) * | 2011-06-03 | 2013-12-19 | Transition Therapeutics Ireland Limited | Scyllo-inositol for the treatment of behavioral and psychiatric disorders |
US9540321B2 (en) | 2013-12-02 | 2017-01-10 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate |
CA3023836C (en) * | 2016-05-18 | 2019-08-27 | Suven Life Sciences Limited | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
SG11201809856SA (en) * | 2016-05-18 | 2018-12-28 | Suven Life Sciences Ltd | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
WO2017199072A1 (en) * | 2016-05-18 | 2017-11-23 | Suven Life Sciences Limited | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
NZ761037A (en) | 2017-07-03 | 2022-10-28 | Suven Life Sciences Ltd | New uses of a pure 5-ht6 receptor antagonist |
-
2020
- 2020-12-02 MX MX2022006535A patent/MX2022006535A/es unknown
- 2020-12-02 CN CN202080090893.7A patent/CN114901282A/zh active Pending
- 2020-12-02 BR BR112022010493A patent/BR112022010493A2/pt unknown
- 2020-12-02 CA CA3162952A patent/CA3162952A1/en active Pending
- 2020-12-02 US US17/780,734 patent/US20220409614A1/en active Pending
- 2020-12-02 AU AU2020398082A patent/AU2020398082A1/en active Pending
- 2020-12-02 IL IL293416A patent/IL293416A/en unknown
- 2020-12-02 KR KR1020227022173A patent/KR20220108123A/ko unknown
- 2020-12-02 WO PCT/IB2020/061383 patent/WO2021111330A1/en active Search and Examination
- 2020-12-02 EP EP20829008.0A patent/EP4069232A1/en active Pending
- 2020-12-02 JP JP2022532840A patent/JP2023506724A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020398082A1 (en) | 2022-06-16 |
WO2021111330A1 (en) | 2021-06-10 |
BR112022010493A2 (pt) | 2022-09-06 |
CA3162952A1 (en) | 2021-06-10 |
US20220409614A1 (en) | 2022-12-29 |
KR20220108123A (ko) | 2022-08-02 |
CN114901282A (zh) | 2022-08-12 |
IL293416A (en) | 2022-07-01 |
AU2020398082A8 (en) | 2022-07-28 |
JP2023506724A (ja) | 2023-02-20 |
EP4069232A1 (en) | 2022-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
ZA200500152B (en) | Use of reboxetine for the treatment of hot flashes | |
RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
WO2006106308A1 (en) | Therapeutic use of nefopam and analogues thereof | |
JP2018522920A5 (es) | ||
Chazan et al. | Ketamine for acute and subacute pain in opioid-tolerant patients | |
JP2016505050A5 (es) | ||
MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
MX2022006535A (es) | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. | |
Shukla et al. | Comparative study of tramadol and diclofenac as analgesic for postoperative pain | |
WO2007062837A2 (en) | Use of a 5-ht4 agonist for the treatment of irritable bowel syndrome characterized by mixed or alternating bowel habits | |
MX2022006537A (es) | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. | |
SE0102887D0 (sv) | New formulation | |
Marinangeli et al. | Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option | |
JP2015515971A5 (es) | ||
RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты | |
MX2022002038A (es) | Composicion farmaceutica para el tratamiento del insomnio. | |
US20220378769A1 (en) | Use of Glutamate 2B Receptor Antagonists and Sigma Receptor Agonists as Antitussives | |
MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
SE0102886D0 (sv) | New formulation | |
MX2022007304A (es) | Uso de lemborexant para tratamiento del insomnio. | |
SE0102888D0 (sv) | New formulation |